Symbiotec Pharmalab IPO Day 3 Subscription Status: 3.82x Subscribed; GMP at ₹340
Symbiotec Pharmalab’s IPO was subscribed 3.82 times on Day 3, as of early afternoon (12:00 noon to 2:00 p.m. IST) on 26 August 2026. Non-Institutional Investors (NIIs) led demand at 7.88x, followed by employees at 4.89x and retail investors at 3.93x. Qualified Institutional Buyers (QIBs) remained at 0.58x. The issue stays open through 27 August, while the latest Grey Market Premium (GMP) was around ₹340.
| Metric | Latest update |
| Bidding day | Day 3, interim |
| Data status | Early afternoon (12:00 noon to 2:00 p.m. IST) on 26 August 2026 |
| Overall subscription | 3.82x |
| QIB subscription | 0.58x |
| NII subscription | 7.88x |
| Retail subscription | 3.93x |
| Employee subscription | 4.89x |
| Current GMP | Around ₹340 |
| GMP percentage | About 34.4% |
| Indicative price | ₹1,328 |
| Closing date | 27 August 2026 |
Symbiotec Pharmalab IPO Day 3 Subscription Status
Day 3 bidding strengthened materially from the previous close, with the NII category recording the highest major-category subscription multiple.
| Investor category | Day 3 interim | Day 2 close | Change |
| Qualified Institutional Buyers (QIBs) | 0.58x | 0.54x | +0.04x |
| Non-Institutional Investors (NIIs) | 7.88x | 2.99x | +4.89x |
| Retail Individual Investors | 3.93x | 2.10x | +1.83x |
| Employees | 4.89x | 3.01x | +1.88x |
| Overall | 3.82x | 1.85x | +1.97x |
Within the NII category, Small Non-Institutional Investors (sNIIs) were subscribed about 9.58x, while Big Non-Institutional Investors (bNIIs) were at about 7.03x. This makes NII demand the clearest driver of the Day 3 acceleration so far.
Subscription multiples measure shares bid for relative to shares reserved in each category. They do not represent the number of unique applicants, and category sizes should be considered when comparing multiples.
How Subscription Changed From Day 2
Overall subscription rose from 1.85x at the Day 2 close to 3.82x during Day 3, an absolute increase of 1.97x.
The NII portion recorded the largest movement, climbing from 2.99x to 7.88x. Retail demand increased from 2.10x to 3.93x, while employee subscription rose from 3.01x to 4.89x.
QIB participation changed much less, moving from 0.54x to 0.58x. As a result, demand remains concentrated among NIIs, retail investors, and employees rather than being broad across all major categories.
Institutional bids often build later in an IPO, but that general pattern does not predict what QIB demand will ultimately reach here.
Symbiotec Pharmalab IPO GMP Today and Estimated Listing Price
The latest available Symbiotec Pharmalab IPO GMP was around ₹340 per share as of early afternoon (12:00 noon to 2:00 p.m. IST) on 26 August 2026.
At the upper price band of ₹988:
Indicative price = ₹988 + ₹340 = ₹1,328
GMP percentage = ₹340 ÷ ₹988 × 100 = about 34.4%
The ₹340 reading is below a previous available reading of roughly ₹352 on 25 August, a decline of ₹12. Other recent trackers have also shown readings around the mid-₹300 range, indicating some variation in the unofficial market.
GMP is unofficial, unregulated, and can change quickly. It is not published by the Securities and Exchange Board of India (SEBI), National Stock Exchange of India (NSE), or BSE Limited (BSE). The ₹1,328 calculation is therefore only indicative and does not guarantee the actual listing price or listing gains.
What Stands Out in Today’s Bidding
The strongest signal is the sharp increase in NII bidding. The category moved from 2.99x at the Day 2 close to 7.88x during Day 3, substantially faster than the overall book.
Retail and employee demand also strengthened, but QIB participation remained below 1x. This leaves the current demand profile uneven.
There is also a mild subscription-GMP divergence. Formal subscription has accelerated sharply, while the latest GMP is below some earlier readings. These indicators measure different things, so the divergence is not inherently contradictory.
Neither high subscription nor a positive GMP proves fair valuation, business quality, or future returns.
IPO Details Retail Investors Need
| IPO detail | Information |
| Price band | ₹938 to ₹988 per share |
| Lot size | 15 shares |
| Minimum retail investment | ₹14,820 at upper band |
| Issue size | About ₹1,757 crore |
| Fresh issue | ₹150 crore |
| Offer for Sale (OFS) | About ₹1,607 crore |
| Issue type | Book-built mainboard IPO |
| Closing date | 27 August 2026 |
| Expected listing date | 1 September 2026 |
| Exchange | NSE and BSE |
The Offer for Sale (OFS) forms most of the issue. Proceeds from the OFS go to selling shareholders rather than to Symbiotec Pharmalab.
Brief Company and Financial Context
Symbiotec Pharmalab develops and manufactures Active Pharmaceutical Ingredients (APIs), complex injectables, and biotechnology-based products, with a significant presence in corticosteroid and steroidal-hormone APIs.
Revenue from operations increased 15.65% from ₹751.55 crore in FY2025 to ₹869.15 crore in FY2026. Total income, which also includes other income, rose from ₹755.98 crore to ₹872.26 crore. Profit After Tax (PAT) increased from ₹96.79 crore to ₹109.90 crore.
The company plans to use about ₹112.5 crore of fresh-issue proceeds to repay or prepay borrowings. Product and customer concentration, regulatory requirements, and the valuation at the upper price band remain important considerations.
What Happens Next
Symbiotec Pharmalab IPO remains open through 27 August 2026. The next update to watch is the closing-day response, particularly the final QIB participation, whether NII and retail demand continues to accelerate, the overall subscription multiple, and any material movement in GMP.
Frequently Asked Questions (FAQs)
Q: How many times was the Symbiotec Pharmalab IPO subscribed on Day 3?
A: Symbiotec Pharmalab IPO was subscribed 3.82x overall as of early afternoon (12:00 noon to 2:00 p.m. IST) on 26 August 2026. NII demand led at 7.88x, retail stood at 3.93x, employees at 4.89x, and QIBs at 0.58x.
Q: How did Symbiotec Pharmalab IPO subscription change from Day 2 to Day 3?
A: Overall subscription increased from 1.85x at the Day 2 close to 3.82x during Day 3, an absolute rise of 1.97x. NII bidding contributed the largest increase, rising from 2.99x to 7.88x.
Q: What is the Symbiotec Pharmalab IPO GMP today?
A: The latest available Grey Market Premium was around ₹340 per share as of early afternoon on 26 August 2026. That was below a previous available reading of roughly ₹352 on 25 August.
Q: What listing price does the current Symbiotec Pharmalab IPO GMP indicate?
A: Adding the ₹340 GMP to the ₹988 upper price band gives an indicative price of about ₹1,328 per share. This represents a GMP of roughly 34.4%, but it is not a guaranteed listing price.
Q: Does a high Symbiotec Pharmalab IPO subscription guarantee a premium listing?
A: No. Subscription reflects formal bidding demand, while GMP is an unofficial market indicator. Neither high subscription nor a positive GMP guarantees a premium listing, fair valuation, or future investment returns.
Disclaimer
The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.
